Log In
Print
BCIQ
Print
Print this Print this
 

Symlin, pramlintide acetate

Also known as: amylin, pramlintide (AC137)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionSynthetic amylin analog
Molecular Target Amylin receptor
Mechanism of ActionAmylin receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsAvoid complications of diabetes; Dampening of blood glucose levels in diabetic patients; Reduce complications of Type I and Type II diabetes; Treat diabetes; Treat Type I and Type II diabetes; Treat Type I diabetic patients failing to achieve glycemic targets with insulin therapy; Treat Type II diabetes; Treat Type II diabetes requiring insulin treatment; Treat Type II diabetic patients failing to achieve glycemic targets with insulin therapy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$11,100.0M

$8,000.0M

$1,400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today